

Translation

Notice: This document is an excerpt translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Tokyo, October 27, 2022
Alfresa Holdings Corporation

**Notice regarding Revisions to the Consolidated Performance Forecast
[Prepared on the Basis of Japan's Generally Accepted Accounting Principles (GAAP)]**

In view of recent performance trends and other factors, Alfresa Holdings Corporation (the Company) has revised its consolidated performance forecast, announced on May 16, 2022, for the first half of fiscal 2022 (April 1, 2022–March 31, 2023). The revised forecast is as follows.

1. Revised Consolidated Performance Forecast for the First Half (April 1, 2022–September 30, 2022) of Fiscal 2022

	Net sales	Operating income	Ordinary profit	Profit attributable to owners of the parent	Earnings per share of common stock
	¥ Million	¥ Million	¥ Million	¥ Million	Yen
Previous forecast (A)	1,304,000	7,600	9,500	5,400	26.68
Revised forecast (B)	1,332,000	11,500	12,800	7,900	39.04
Change (B-A)	28,000	3,900	3,300	2,500	-
Percentage change (%)	2.1	51.3	34.7	46.3	-
(Ref.) Results for the first half of the previous fiscal year (first half of fiscal 2021)	1,288,706	9,117	10,956	6,988	33.02

2. Reason for Revisions of Consolidated Performance Forecast

The Company expects that its net sales, operating income, ordinary profit, and profit attributable to owners of the parent for the period of the first half of fiscal 2022 will exceed its previous forecast, reflecting factors including an increase in the sales of medical goods, and efforts to curb selling, general and administrative expenses for the Group as a whole, in addition to the higher-than-expected growth of the ethical pharmaceuticals market.

* The above forecast was prepared on the basis of available information at the time of the release of this notice. Actual performance may differ from the forecasted figures due to various factors arising in the future.

About **Alfresa Group**

The Alfresa Group is a leader in the Japanese healthcare industry, which is dedicated to making its corporate philosophy, “we create and deliver a fresh life for all,” come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, and operating dispensing pharmacies. Alfresa Holdings Corporation (TSE:2784) reported its consolidated revenue of ¥2.5 trillion for the fiscal year ended March 31, 2022. For more information, please see: <https://www.alfresa.com/eng/>